证券代码：002162 证券简称：悦心健康 公告编号：2024-003 上海悦心健康集团股份有限公司 关于回购公司股份方案的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，不存在虚假记载、 误导性陈述或者重大遗漏。 重要内容提示： 1、拟回购股份基本情况 （1）拟回购资金总额：不低于人民币2,000万元（含），不超过人民币3,000万 元（含）； （2）拟回购股份的种类：公司已发行的人民币普通股（A股）股票； （3）拟回购用途：股权激励计划或员工持股计划； （6）实施期限：自董事会审议通过本回购方案之日起12个月内； （7）资金来源：自有资金。 如国家对相关政策作调整，则本回购方案按调整后的政策实行。 2、相关股东是否存在减持计划 截至本公告日，公司董事、监事、高级管理人员、控股股东及其一致行动人目 前暂无明确的减持公司股份计划，如后续新增减持股份计划，将按照相关规定及时 履行信息披露义务。 （4）拟回购价格：不超过人民币5元/股（含）； （5）拟回购数量：按本次拟用于回购的资金总额上限及回购价格上限测算，预 计回购股份数量约为600万股，约占公司总股本的比例为0.65%；按本次拟用于回购 的资金 ...

证券代码：002162 证券简称：悦心健康 公告编号：2024-002 上海悦心健康集团股份有限公司 第八届董事会第五次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、董事会会议召开情况 上海悦心健康集团股份有限公司（以下简称"公司"）第八届董事会第五次会议 于 2024 年 2 月 19 日以电子邮件的方式发出通知，会议于 2024 年 2 月 23 日在上海 市闵行区浦江镇恒南路 1288 号会议室以现场结合通讯方式召开。 会议由董事长李慈雄先生主持，应出席会议的董事 9 人，实际出席会议的董事 9 人，公司部分监事、高级管理人员列席了会议。本次会议的召开符合有关法律、行 政法规、部门规章、规范性文件和公司《章程》的规定，合法有效。 基于对公司未来发展的信心和对公司价值的认可，为维护公司全体股东利益， 增强投资者信心，稳定及提升公司价值，切实保护全体股东的合法权益，结合公司 经营情况及财务状况等因素，同意公司以自有资金回购公司已发行的人民币普通股 （A 股）股票，并在未来将前述回购股份用于股权激励或员工持股计划。本次回购 资金总额不低于人民 ...

Financial Performance - The company's operating revenue for Q3 2023 was ¥371,001,354.81, representing a 5.94% increase compared to the same period last year[5] - The net profit attributable to shareholders was -¥59,697,962.47, a decrease of 22.42% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥62,341,777.99, a decrease of 4.14% compared to the previous year[5] - The net profit for the third quarter was ¥108,175,712.20, a significant recovery from a net loss of ¥85,451,485.09 in the previous year[21] - The net profit attributable to the parent company for Q3 2023 was ¥108,847,069.54, compared to a net loss of ¥85,563,339.86 in the same period last year, indicating a significant turnaround[22] - The total comprehensive income for the period was ¥40,098,875.01, compared to a loss of ¥79,388,703.75 in Q3 2022, reflecting improved financial performance[22] Assets and Liabilities - The total assets at the end of Q3 2023 were ¥2,333,047,780.63, a decrease of 6.32% from the end of the previous year[5] - The company's total assets decreased to ¥2,333,047,780.63 from ¥2,490,346,685.37, representing a decline of 6.3%[18] - Current liabilities decreased to ¥790,366,278.94 from ¥953,990,135.67, a reduction of 17.1%[18] - Long-term borrowings stood at ¥292,500,000.00, slightly down from ¥303,750,000.00, indicating a decrease of 4.1%[18] - The company's cash and cash equivalents decreased to ¥275,819,976.47 from ¥336,370,657.88, a decline of 18.0%[18] Equity and Shareholder Information - The equity attributable to shareholders increased to ¥1,048,349,523.62, reflecting a growth of 4.19% year-on-year[5] - The total equity attributable to shareholders increased to ¥1,048,349,523.62 from ¥1,006,236,659.41, reflecting a growth of 4.2%[18] - The total number of ordinary shareholders at the end of the reporting period was 62,583[13] Cash Flow - The company reported a net cash flow from operating activities of ¥53,826,852.77, which is a 265.19% increase year-to-date[5] - The net cash flow from operating activities improved to ¥53.83 million, a substantial increase of ¥86.41 million compared to a negative cash flow of ¥32.58 million in the previous year, attributed to enhanced collection efforts[11] - Operating cash flow for the period was ¥53,826,852.77, a recovery from a negative cash flow of ¥32,584,807.01 in the previous year[24] - The company’s cash flow from financing activities was negative at ¥121.88 million, a decrease of 566.04% compared to the previous year, primarily due to the repayment of part of the borrowings[11] - The company reported a net cash outflow from financing activities of ¥121,880,570.09, compared to a smaller outflow of ¥18,299,261.96 in the previous year[25] - The cash and cash equivalents at the end of the period stood at ¥140,751,952.01, slightly down from ¥141,167,358.41 at the beginning of the period[25] Investment and Income - Interest income for the first nine months of 2023 reached ¥3.51 billion, a significant increase of 78.10% compared to ¥1.97 billion in the same period of 2022, primarily due to the receipt of technology development equity transfer payments and increased deposits[10] - Investment income for the first nine months of 2023 was ¥174.59 million, a significant increase of 7816.45% compared to a loss of ¥2.26 million in the same period last year, mainly due to gains from the transfer of technology development and Shanghai Yuexin Comprehensive Clinic equity[10] - The company reported an investment income of ¥174,586,483.93, a significant improvement from a loss of ¥2,262,522.17 in the same period last year[21] Expenses and Losses - Operating costs for the third quarter were ¥927,455,998.31, up from ¥854,966,557.33, reflecting a rise of 8.5% year-over-year[21] - Research and development expenses for the quarter were ¥7,897,484.64, compared to ¥7,006,293.99 in the previous year, marking an increase of 12.7%[21] - The company recorded a credit impairment loss of ¥88.76 million, an increase of 116.77% from ¥40.94 million in the previous year, due to higher provisions for bad debts based on assessments of certain real estate clients[10] - The company reported a decrease in asset impairment losses to ¥5.53 million, a reduction of 86.99% from ¥42.50 million in the previous year, as there were no significant asset disposals this year[10] - The company had no significant asset disposals this period, leading to a decrease in asset disposal losses to ¥260.32 thousand, down 93.79% from ¥4.19 million in the previous year[10] Other Financial Metrics - The diluted earnings per share for Q3 2023 was ¥0.1175, a recovery from a loss of ¥0.0924 per share in the same quarter last year[22] - The company experienced a significant increase in contract liabilities, which rose by 48.78% to ¥54,869,942.26, attributed to pre-received tuition fees[9] - The company recognized non-recurring gains of ¥2,643,815.53 in Q3 2023, primarily from government subsidies and asset disposals[6] - The long-term equity investment increased by 367.94% to ¥258,176,726.49 due to the transfer of equity in a subsidiary[9] - The company established a new subsidiary, Wenzhou Oriental Yueshin Vocational School, leading to increased long-term expenses[9] - Cash flow from investing activities showed a net inflow of ¥67.61 million, a 186.56% increase from a net outflow of ¥78.11 million in the same period last year, primarily due to the return of short-term loans[11] - The company experienced a net increase in cash flow from investment activities of ¥67,610,368.90, compared to a net outflow of ¥78,107,025.37 in the previous year[24] - The total cash inflow from financing activities was ¥297,341,881.54, down from ¥646,705,336.43 in the previous year[25] - The company reported a decrease in other comprehensive income attributable to the parent company, amounting to -¥68,067,953.29, compared to a positive income of ¥6,124,647.42 in the same period last year[22]

上海悦心健康集团股份有限公司 证券代码：002162 证券简称：悦心健康 公告编号：2023-048 关于控股股东股份减持计划提前终止的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 上海悦心健康集团股份有限公司 董事会 二○二三年八月三十日 上海悦心健康集团股份有限公司（以下简称"公司"）于 2023 年 7 月 4 日披露 了《关于控股股东减持比例达 1%暨减持计划实施完毕及后续减持计划的预披露公告》 （公告编号：2023-046），公司控股股东 CIMIC INDUSTRIAL INC.（中文名称："斯米 克工业有限公司"，以下简称"斯米克工业"）计划在公告披露之日起 15 个交易日后 的 6 个月内通过集中竞价交易方式减持公司股份不超过 18,530,000 股（占公司股份 总数 2%）。 近日，公司收到控股股东斯米克工业出具的《关于提前终止股份减持计划的通 知》，根据中国证券监督管理委员会于 2023 年 8 月 27 日发布的《证监会进一步规范 股份减持行为》的相关要求，结合上市公司具体情况，斯米克工业决定提前终止本次 减持计划。 特此公告。 ...

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 567.32 million, representing a 13.58% increase compared to CNY 499.49 million in the same period last year[20]. - The net profit attributable to shareholders of the listed company reached CNY 168.55 million, a significant increase of 2,057.82% from a loss of CNY 8.61 million in the previous year[20]. - The net cash flow from operating activities improved to CNY 13.87 million, a 164.97% increase from a negative cash flow of CNY 21.35 million in the same period last year[20]. - The basic earnings per share rose to CNY 0.1819, compared to a loss of CNY 0.0093 per share in the previous year, marking a 2,055.91% increase[20]. - The total profit for the first half of 2023 was CNY 178,386,065.81, compared to a loss of CNY 15,616,341.67 in the same period last year[155]. - The company reported a net loss of CNY 155,105,758.00 for the first half of 2023, an improvement from a net loss of CNY 323,650,790.01 in the same period of 2022[152]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 2.43 billion, a decrease of 2.33% from CNY 2.49 billion at the end of the previous year[20]. - The total liabilities decreased to RMB 1,200,000,000.00, down from RMB 1,250,000,000.00, reflecting a reduction of 4%[148]. - The total assets as of June 30, 2023, amounted to CNY 2,380,240,176.00, slightly down from CNY 2,387,433,939.06 at the beginning of the year[152]. - The total equity of the company as of June 30, 2023, was RMB 1,232,362,399.27, down from RMB 1,240,346,685.37 at the beginning of the year[148]. Revenue Breakdown - In the first half of 2023, the company's ceramic tile business achieved revenue of 478 million yuan, a year-on-year increase of 15%, despite the overall domestic ceramic tile production declining by 15.10%[39]. - Tile sales contributed CNY 478 million, accounting for 84.4% of total revenue, with a growth of 15.24% year-on-year[48]. - The health and wellness (care/medical) business generated CNY 45 million, with a year-on-year increase of 6.47%[48]. - The company's revenue for the reporting period reached ¥567,322,497.67, representing a year-on-year increase of 13.58%, primarily driven by a 16% rise in tile sales revenue due to enhanced project follow-up and distribution channel layout[53]. Investment and Acquisitions - The company has no plans for major acquisitions or new product launches announced during this reporting period[4]. - The company is exploring potential mergers and acquisitions to bolster its market share and diversify its product offerings[167]. - The company transferred control of its subsidiary to reduce operational risks and secure funding for land development projects[47]. Research and Development - Research and development expenses amounted to ¥17,140,747.30, up 16.05% year-on-year, attributed to increased small-scale trial costs[53]. - The company launched 23 new products in the first half of 2023, with new product sales accounting for 18% of total revenue[41]. - Research and development expenses for the first half of 2023 were approximately 73 million yuan, representing an increase of 35% year-on-year[171]. Market Strategy - The company is actively expanding its market presence, with a focus on both domestic and international sales channels, including e-commerce and direct sales[31]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[154]. - The company is focusing on maintaining its competitive edge in the healthcare sector amidst potential policy changes and market competition[74]. Environmental and Social Responsibility - The company has invested RMB 2.1088 million in environmental governance and protection in the first half of 2023[92]. - The company has established a zero discharge policy for industrial wastewater, utilizing two large wastewater treatment stations[90]. - The company’s emissions of smoke and pollutants are compliant with the relevant standards, with specific measures in place for dust and wastewater treatment[90]. Shareholder Information - The company will not distribute cash dividends or bonus shares for the half-year period[79]. - The total number of shareholders at the end of the reporting period is 73,702[133]. - CIMIC Industrial Inc. holds 37.41% of the shares, totaling 346,631,164 shares, with a decrease of 16,105,000 shares during the reporting period[133]. Governance and Compliance - The company has established a robust governance framework to support its growth and ensure compliance with regulatory requirements[179]. - The financial statements are prepared based on the going concern principle, confirming the company's ability to continue operations for at least the next 12 months[188]. - The company has not reported any new product launches or technological advancements in this period[174].

上海悦心健康集团股份有限公司 独立董事关于控股股东及其他关联方占用公司资金、公司对外担保情况的 专项说明和独立意见 根据《上市公司独立董事规则》、《深圳证券交易所股票上市规则》、《深圳证券交易 所上市公司自律监管指引第 1 号——主板上市公司规范运作》等相关法律、法规和规范 性文件以及《公司章程》等规定和要求，作为上海悦心健康集团股份有限公司（以下简 称"公司"）的独立董事，基于独立判断立场，我们对 2023 年半年度（以下简称"报告 期"）公司对外担保、公司控股股东及其他关联方占用公司资金等情况进行了认真细致 的核查，发表如下专项说明和独立意见： 一、关于公司对外担保情况的专项说明及独立意见 根据《上市公司监管指引第 8 号——上市公司资金往来、对外担保的监管要求》， 我们对公司累计和当期对外担保情况进行了仔细的核查，发表专项说明和独立意见如 下： 1、报告期内，公司对外提供担保均已按照有关法律、法规及《公司章程》的规定履行 了相关审议程序，不存在违规担保情况。 根据《上市公司监管指引第 8 号——上市公司资金往来、对外担保的监管要求》， 我们对公司与控股股东及其他关联方的资金往来进行了仔细的核查，发表专项 ...

2023年半年度非经营性资金占用及其他关联资金往来情况汇总表 附件一 企业负责人： 主管会计工作的负责人： 会计机构负责人： | 上市公司名称：上海悦心健康集团股份有限公司 | | | | | | | | | | | 单位：万元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 占用方与上市公司的关联 | 上市公司核算的 | 2023年期初占 | 2023年1-6月占用累计发 | 2023年1-6月占用 | 2023年1-6月偿还累计 | 2023年6月30日 | | | | | 非经营性资金占用 | 资金占用方名称 | 关系 | 会计科目 | 用资金余额 | 生金额(不含利息） | 资金的利息 | 发生金额 | 占用资金余额 | | 占用形成原因 | 占用性质 | | 控股股东、实际控制人及其附 | | | | | | | | | | | | | 属企业 | | | | | | | | | | | | | 小计 | - | - | - | - | - | - | - | | - | - | - ...

证券代码：002162 证券简称：悦心健康 上海悦心健康集团股份有限公司投资者关系活动记录表 编号：202302 | --- | --- | --- | |--------------------|----------------------------------------------------------|----------------------------------| | 投资者关系活动类别 | √特定对象调研 □分析师会议□媒体采访 □新闻发布会 □路演活动 | □业绩说明会 | | | □现场参观 | □其他 （请文字说明其他活动内容） | 活动参与人员 华西证券 许光辉 时间 2023 年 6 月 27 日 15:00-16:30 地点 上海市闵行区浦江镇恒南路 1288 号公司会议室 | --- | --- | |-------------------------|-------| | 副总裁 何志明 | | | 董事会秘书 程 | 梅 | | 金海悦心颐养院负责人 王 | 璐 | | 证券事务代表 莫丹丹 | | 上市公司接待 人员 形式 现场会议 一、公司基本情况介绍 公司上半年瓷 ...

Financial Performance - The company's revenue for Q1 2023 was ¥221,065,012.52, representing an increase of 18.52% compared to ¥186,519,515.45 in the same period last year[5] - The net profit attributable to shareholders was -¥7,672,898.23, an improvement of 49.83% from -¥15,294,690.85 year-on-year[5] - The net cash flow from operating activities improved by 55.51%, reaching -¥43,674,374.02 compared to -¥98,177,017.43 in Q1 2022[13] - The company reported a 288.99% increase in investment income, amounting to ¥2,208,237.86, primarily due to dividends received from an associate[11] - The gross profit from tile sales increased by approximately 22% year-on-year, contributing an additional ¥5,500,000 to gross profit[12] - Total operating revenue for Q1 2023 was CNY 221,065,012.52, an increase of 18.5% compared to CNY 186,519,515.45 in the same period last year[20] - Net loss for Q1 2023 was CNY 7,679,632.24, compared to a net loss of CNY 15,314,285.60 in Q1 2022, representing a 50.2% improvement[22] - Basic and diluted earnings per share for Q1 2023 were both CNY -0.0083, an improvement from CNY -0.0165 in Q1 2022[22] Cash Flow - The net cash flow from financing activities significantly increased by 290.91%, reaching ¥72,231,449.31 compared to -¥37,836,020.70 in the same period last year[13] - The net cash flow from operating activities increased year-on-year due to higher sales receipts[15] - The net cash flow from investing activities increased year-on-year due to government compensation received for land[15] - Cash inflow from operating activities totaled CNY 303,136,419.50, compared to CNY 258,874,466.32 in the same period last year, reflecting a growth of 17.1%[23] - The total cash and cash equivalents at the end of the period amounted to ¥165,799,949.86, an increase from ¥141,167,358.41 at the beginning of the period[24] - The company experienced a net increase in cash and cash equivalents of ¥24,632,591.45, contrasting with a decrease of -¥149,926,772.02 in the previous period[24] - The company received cash from borrowings totaling ¥100,000,000.00[24] - The company distributed dividends and interest payments totaling ¥8,485,965.13[24] Assets and Liabilities - Total assets decreased by 2.38% to ¥2,431,037,643.33 from ¥2,490,346,685.37 at the end of the previous year[5] - The total assets amounted to 2,431,037,643.33 yuan, a decrease from 2,490,346,685.37 yuan at the beginning of the year[18] - Current liabilities totaled 902,864,858.04 yuan, down from 953,990,135.67 yuan at the beginning of the year[18] - The company's long-term borrowings were 300,000,000 yuan, slightly down from 303,750,000 yuan at the beginning of the year[18] - The total liabilities were 1,407,361,703.10 yuan, a decrease from 1,473,317,979.11 yuan at the beginning of the year[18] - The company's capital reserve increased to 196,283,288.37 yuan from 195,436,092.77 yuan at the beginning of the year[18] - The company reported a total of 898,448,318.05 yuan in current assets, down from 942,685,963.79 yuan at the beginning of the year[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 71,020, with no preferred shareholders having restored voting rights[14] - CIMIC INDUSTRIAL INC. holds 38.41% of shares, amounting to 355,896,164 shares, with 100 million shares pledged[14] Research and Development - The company received government subsidies of ¥166,563.40 related to R&D investments during the reporting period[6] - Research and development expenses for Q1 2023 were CNY 1,768,801.66, a decrease of 19.9% from CNY 2,210,031.22 in the same period last year[20] Other Information - The company established a new non-wholly-owned subsidiary, resulting in a 124.75% increase in minority interests to ¥24,254,863.72[9] - The impact of exchange rate changes on cash and cash equivalents was a decrease of -¥11,112.98[24] - The company did not undergo an audit for the first quarter report[25] - The report was presented by the board of directors on April 26, 2023[26]